{"entity":{"id":"nct06117774","kind":"trial","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","aka":["DeLLphi-306"],"tldr":"A phase 3 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) is a phase 3 interventional study registered as NCT06117774 by Amgen, with 404 participants enrolled, started 2024-02-20 and due to reach its primary completion in 2030-04-20. Interventions recorded: Tarlatamab, Placebo. Conditions listed: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06117774","url":"https://clinicaltrials.gov/study/NCT06117774"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","limited-stage-sclc"],"sections":[],"technologies":["t-cell-engager"],"targets":[],"drugs":["tarlatamab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06117774","phase":"3","setting":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy","sponsor":"Amgen","participation":[{"nct":"NCT06117774","source":"https://clinicaltrials.gov/study/NCT06117774","fetchedAt":"2026-10-07T16:54:14.819Z","studySha256":"74f0e41b273bdc9d69b32524a6581d52faba73b514df49f365801f2263796a8d","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-29","leadSponsor":"Amgen","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":404,"enrolmentType":"ACTUAL","siteCount":204,"recruitingSiteCount":0,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","China","Colombia","France","Germany","Greece","Hong Kong","Italy","Japan","Mexico","Poland","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-02-20","startedType":"actual","enrolled":404,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06117774/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}